Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald J Buchsbaum

Showing results (11-20 of 157) with videos related to

Pageof 16
Sort By:
Molecular Imaging and Biology|November 11, 2015
A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse ModelsHarrison Kim, Donald J Buchsbaum, Kurt R Zinn
Frontiers in Oncology|September 30, 2022
Editorial: Targeting the Wnt/β-catenin signaling pathway in cancerSimone Patergnani, Donald J Buchsbaum, Gary A Piazza
Future Oncology (London, England)|August 23, 2006
TRAIL receptor-targeted therapyDonald J Buchsbaum, Tong Zhou, Albert F Lobuglio
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Radiotargeted gene therapyDonald J Buchsbaum, Tandra R Chaudhuri, Kurt R Zinn
Gynecologic Oncology|July 20, 2010
Overcoming TRAIL resistance in ovarian carcinomaKerri S Bevis, Donald J Buchsbaum, J Michael Straughn
Frontiers in Oncology|September 25, 2025
Editorial: RAS inhibitor therapy of cancerDonald J Buchsbaum, Nicolas N Nassar, Gary A Piazza
Future Oncology (London, England)|July 31, 2007
TRAIL-receptor antibodies as a potential cancer treatmentDonald J Buchsbaum, Andres Forero-Torres, Albert F LoBuglio
Bioconjugate Chemistry|March 22, 2002
De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agentAhmad Safavy, Dale C Smith, Alireza Bazooband, et al.
Bioconjugate Chemistry|March 22, 2002
Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agentAhmad Safavy, Dale C Smith, Alireza Bazooband, et al.
Journal of the Egyptian National Cancer Institute|September 20, 2015
Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancerWaleed Arafat, Tong Zhou, George E Naoum, et al.
Pageof 16

Showing results (11-20 of 157) with videos related to

Sort By:
Pageof 16
Molecular Imaging and Biology|November 11, 2015
A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse ModelsHarrison Kim, Donald J Buchsbaum, Kurt R Zinn
Frontiers in Oncology|September 30, 2022
Editorial: Targeting the Wnt/β-catenin signaling pathway in cancerSimone Patergnani, Donald J Buchsbaum, Gary A Piazza
Future Oncology (London, England)|August 23, 2006
TRAIL receptor-targeted therapyDonald J Buchsbaum, Tong Zhou, Albert F Lobuglio
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Radiotargeted gene therapyDonald J Buchsbaum, Tandra R Chaudhuri, Kurt R Zinn
Gynecologic Oncology|July 20, 2010
Overcoming TRAIL resistance in ovarian carcinomaKerri S Bevis, Donald J Buchsbaum, J Michael Straughn
Frontiers in Oncology|September 25, 2025
Editorial: RAS inhibitor therapy of cancerDonald J Buchsbaum, Nicolas N Nassar, Gary A Piazza
Future Oncology (London, England)|July 31, 2007
TRAIL-receptor antibodies as a potential cancer treatmentDonald J Buchsbaum, Andres Forero-Torres, Albert F LoBuglio
Bioconjugate Chemistry|March 22, 2002
De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agentAhmad Safavy, Dale C Smith, Alireza Bazooband, et al.
Bioconjugate Chemistry|March 22, 2002
Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agentAhmad Safavy, Dale C Smith, Alireza Bazooband, et al.
Journal of the Egyptian National Cancer Institute|September 20, 2015
Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancerWaleed Arafat, Tong Zhou, George E Naoum, et al.
Pageof 16